Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&D
11.4.2022 15:00:00 EEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services. The strategic partnership will encompass multiple strategic and commercial initiatives, including NeoGenomics labs offering access to Biognosys proteomics platforms, medical and scientific affairs-joint presentations and discussions, along with joint scientific and technical initiatives.
“At Biognosys, we continuously push the boundaries of what is possible with our proteomics solutions to address key challenges in drug development,” said Kristina Beeler, Ph.D., Chief Business Officer, Biognosys. “Our platforms are transforming research from early drug discovery to clinical biomarker identification. We are excited to now combine our proteomics platforms with NeoGenomics’ immuno-profiling platform to advance our biopharma partners’ oncology drug development programs.”
One of the first efforts of this collaboration saw Biognosys combining its TrueDiscovery™ proteomics platform with NeoGenomics’ MultiOmyx™ multiplexed immunofluorescence (mIF) spatial tissue analysis as a multimodal approach for analyzing the proteins of tumor samples from late-stage melanoma patients treated with immune-checkpoint inhibitors. The dual proteomic and mIF profiling approach allows for a comprehensive characterization of melanoma patients and pinpointed a specific set of biomarkers that may be used to predict a patient’s response to checkpoint inhibitors. The development and utility of this multimodal approach will be presented across two posters by Biognosys and NeoGenomics at the 2022 American Association for Cancer Research (AACR) annual meeting this week. The multimodal offering will also be made available commercially for biopharma partners.
“The need of our pharma customers to access the next state-of-the-art technology to improve diagnostics and clinical trials is top priority for us,” said Gina Wallar, Ph.D., President, Pharma Services, NeoGenomics Laboratories, Inc. “Partnering with Biognosys gives us the added advantage of expanding into proteomics, data analytics and subsequent actionable results, not only in early discovery and translational research but ultimately, in clinical trials impacting patient care.”
AACR Posters
Abstract 3923 : Ubiquitin ligases implicated as predictive biomarkers for poor outcome to immunotherapy in melanoma patients
In this poster presented by Biognosys on April 13, unbiased proteomic profiling with TrueDiscovery was used to characterize melanoma patients and their responses to PD1-targeted immunotherapy. The profiling was able to identify a set of 103 proteomic biomarkers associated with ubiquitination pathways that correlate with treatment outcomes. The results were cross analyzed with the spatial tissue analysis performed via the MultiOmyx platform. These findings need to be further confirmed in orthogonal cohorts, nevertheless the data point to the possibility of more precise targeting of melanoma patients for immunotherapy.
Abstract 1267 : Dual approach using unbiased proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients
Despite clinical advances, durable responses to immune checkpoint inhibitors are not observed in 40-60% of melanoma patients, and current biomarkers do not clearly distinguish responders. In this study presented by NeoGenomics today, a dual proteomic and mIF profiling approach was able to comprehensively characterize melanoma patients and successfully stratify non-responders from responders based on a set of selected protein biomarkers.
To see Biognosys’ full presence at the AACR 2022 annual meeting, please refer to this press release or visit biognosys.com/aacr22.
About TrueDiscovery™
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad, Fresno and San Diego, California; Houston, Arizona, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit neogenomics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005058/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
Media Contact NeoGenomics, Inc.
Madhushree Ghosh
Vice-President, Global Strategic Alliances & Projects
Phone +1 858 342 2724
madhushree.ghosh@neogenomics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arc'teryx Introduces System 0™, a New Framework for the Future of Product Design and Circularity26.8.2026 16:00:00 EEST | Press release
Arc'teryx Equipment, the global design company specializing in technical high-performance apparel and equipment, today introduced System 0™, a new framework that reimagines how products can be designed, manufactured, used, repaired, and ultimately regenerated. System 0 represents the next evolution for sustainability in the outdoor industry, as it embeds circular thinking across an entire product lifecycle while maintaining the uncompromising performance standards that define the Arc’teryx brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826686539/en/ Arc’teryx athlete, Craig Murray, wearing the Sperro SV, a multisport mountain-grade hardshell built with circular design principles, available September 4, 2026. The first product being introduced as part of the System 0 platform is the Sperro SV jacket, a multisport mountain-grade hardshell engineered for durability, repairability, and disassembly at end of life – the
Xsolla Announces Five-Year Partnership With the Global Esports Federation26.8.2026 16:00:00 EEST | Press release
Xsolla, a global commerce company, today announced a landmark five-year strategic partnership with the Global Esports Federation (GEF), the world-convening body for esports. As GEF's exclusive partner for commerce, payments, wallet, loyalty, and distribution, Xsolla will power the entire GEF ecosystem, including the flagship Global Esports Games, pro-series Global Esports Tour, global GEFcon, and 180+ Member Federations across five continents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826948844/en/ Graphic: Xsolla The announcement comes as GEF marks 100 days to go to the Los Angeles 2026 Global Esports Games (GEGLA26), adding further momentum to the road to Los Angeles and GEF’s flagship global esports celebration this December. The partnership launches at the GEGLA26, where Xsolla will begin serving as the unified commerce and payments layer for the GEF ecosystem. Across GEF properties, in more than 200 markets, Xso
FlightSafety International Reaches Agreement to Acquire Acron Technologies’ Commercial Training Solutions26.8.2026 16:00:00 EEST | Press release
FlightSafety International Inc. (FSI), a leading global provider of aviation training and simulation technology, today announced it has signed a definitive agreement with Acron Technologies, a portfolio company of TJC LP, to acquire its Commercial Training Solutions (CTS) business, including its Training Systems, Training Services, Aviation Academy, and Driver Training portfolio. The agreement marks a significant expansion of FSI’s capabilities in the commercial aviation market, broadening and complementing its simulator manufacturing capabilities and global training footprint. CTS brings over eight decades of experience in commercial aviation training and simulation. With a long-standing heritage in commercial airline simulator manufacturing, CTS has delivered more than 850 training devices throughout its history, with over 300 full-flight simulators currently in operation worldwide today. Its training and manufacturing locations across the U.S., U.K., and Thailand support pilot and d
NABEP Appoints Sara Chouraqui as General Counsel26.8.2026 16:00:00 EEST | Press release
North American Blue Energy Partners (NABEP) has appointed Sara Chouraqui as General Counsel, with Elizabeth Collery and Victoria Jacobson each joining as Deputy General Counsel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826168543/en/ Sara Chouraqui joins NABEP as its General Counsel, bringing decades of legal expertise. These additions significantly strengthen NABEP’s senior leadership team and legal expertise as the company improves its operations, increases production and develops new strategic and commercial partnerships. As General Counsel, Chouraqui will lead NABEP’s global legal function and advise the company’s leadership on its legal, regulatory and corporate priorities, including major transactions and partnerships, governance, compliance and the management of legal and regulatory risk across the company’s operations. Her experience navigating complex cross-border legal and regulatory matters will be particu
Grafana Labs Crosses 10,000-Customer Milestone as AI Adoption Accelerates Growth Across the Platform26.8.2026 16:00:00 EEST | Press release
Grafana Labs, the company behind the open observability cloud, today announced it has crossed 10,000 customers worldwide and surpassed $600 million in annual recurring revenue, as organizations standardize on open observability for the AI era. Teams need AI to help them understand their own systems faster, especially as complexity and overhead remain the top observability concern cited in Grafana Labs' 2026 Observability Survey – a need reflected by the adoption of Grafana Assistant, Grafana Cloud's context-aware AI agent for exploring and troubleshooting observability data, now used by more than 18,000 organizations. Teams also need observability purpose-built for AI systems themselves: When teams move AI into production, models drift, agents take unexpected actions, token costs spike without warning, and the latency and error signals that caught problems for the last decade don't explain what went wrong. The same survey found 57% of organizations are now implementing LLM observabilit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom